Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), in a Two Drug Regimen, Proves Safe and Effective for Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference.
- LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference.
- Dr Dong Xie, Chief Scientific Officer, Chairman, Frontier Biotechnologiessaid, "We are honored to present at EACS and contribute to knowledge-building in the field of HIV/AIDS treatment.
- Critically-ill hospitalized AIDS patients represent an important and difficult to treat patient group.
- Currently there is limited data on antiviral therapy for hospitalized AIDS patients with complicated opportunistic infections.